Difference between revisions of "Vincristine (Oncovin)"
Jump to navigation
Jump to search
m |
m |
||
| Line 27: | Line 27: | ||
*[[Marginal zone lymphoma]] | *[[Marginal zone lymphoma]] | ||
*[[Mediastinal gray-zone lymphoma]] | *[[Mediastinal gray-zone lymphoma]] | ||
| + | *[[Medulloblastoma]] | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
*[[Penile cancer]] | *[[Penile cancer]] | ||
| Line 133: | Line 134: | ||
[[Category:Marginal zone lymphoma medications]] | [[Category:Marginal zone lymphoma medications]] | ||
[[Category:Mediastinal gray-zone lymphoma medications]] | [[Category:Mediastinal gray-zone lymphoma medications]] | ||
| + | [[Category:Medulloblastoma medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:Penile cancer medications]] | [[Category:Penile cancer medications]] | ||
Revision as of 05:52, 30 September 2018
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Anaplastic glioma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- Chronic lymphocytic leukemia (CLL/SLL)
- CNS lymphoma
- Diffuse large B-cell lymphoma
- Ewing's sarcoma
- Extranodal NK/T-cell lymphoma, nasal type
- Follicular lymphoma
- Glioblastoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Low-grade glioma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Medulloblastoma
- Multiple myeloma
- Penile cancer
- Peripheral T-cell lymphoma
- Pheochromocytoma
- Post-transplant lymphoproliferative disorder
- Primary mediastinal B-cell lymphoma
- Soft tissue sarcoma
- Small cell lung cancer
- T-cell acute lymphoblastic leukemia
- Testicular cancer
- Thrombotic thrombocytopenic purpura
- Thymoma
- Transformed lymphoma
- Vascular sarcoma
- Waldenström macroglobulinemia
Diseases for which it was used
Notable side effects
- Neuropathy [3]
Patient drug information
- Vincristine (Oncovin) patient drug information (Chemocare)[4]
- Vincristine (Oncovin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 7/10/1963: Initial FDA approval
Also known as
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Alcrist | Biocrist | Biocrystin | Cellcristin | Citomid | Crivosin | Cytomid | Farmistin CS |
| Fauldvincri | Krebin | Kyocristine | Nevexitin | Onkocristin | Pericristine | Pharmacristine | Tecnocris |
| Vincasar | Vinces | Vincosid | Vincran | Vincrex | Vincrifil | Vincrin | Vincrisin |
| Vincrisol | Vincristin | Vincristina | Vincristinesulfaat | Vincristinsulfat | Vincristinum | Vincrisul | Vinracin |
| Vinracine | Vinstin | Vintec | |||||
References
- ↑ 1.0 1.1 Vincristine (Oncovin) package insert
- ↑ Vincristine (Oncovin) package insert (locally hosted backup)
- ↑ Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. Epub 2010 Sep 21. link to original article contains verified protocol PubMed
- ↑ Vincristine (Oncovin) patient drug information (Chemocare)
- ↑ Vincristine (Oncovin) patient drug information (UpToDate)
Categories:
- Drugs
- Intravenous medications
- Vesicant chemotherapy
- Microtubule inhibitors
- Vinca alkaloids
- Adult T-cell leukemia-lymphoma medications
- Anaplastic glioma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Breast cancer medications (historic)
- Burkitt lymphoma medications
- CNS lymphoma medications
- Chronic lymphocytic leukemia (CLL/SLL) medications
- Colon cancer medications (historic)
- Diffuse large B-cell lymphoma medications
- Ewing's sarcoma medications
- Extranodal NK/T-cell lymphoma, nasal type medications
- Follicular lymphoma medications
- Glioblastoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Medulloblastoma medications
- Multiple myeloma medications
- Penile cancer medications
- Peripheral T-cell lymphoma medications
- Pheochromocytoma medications
- Post-transplant lymphoproliferative disorder medications
- Primary mediastinal B-cell lymphoma medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- T-cell acute lymphoblastic leukemia medications
- Testicular cancer medications
- Thrombotic thrombocytopenic purpura medications
- Thymoma medications
- Transformed lymphoma medications
- Vascular sarcoma medications
- Waldenström macroglobulinemia medications
- FDA approved in 1963
- WHO Essential Cancer Medicine